VYNE stock funds Yarrow Bioscience after USD 172.5 million offering
Published on 09/30/2026 at 22:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
VYNE stock is now represented by Yarrow Bioscience, which raised USD 172.5 million in a public offering that closed on September 14, 2026. The financing gives the clinical-stage biotechnology company capital for its autoimmune thyroid disease pipeline.
Offering adds USD 172.5 million
According to Business Wire on September 14, 2026, Yarrow sold 6,634,615 shares at USD 26.00 each. The underwriters exercised their full option for 865,384 additional shares, taking gross proceeds to USD 172.5 million.
The proceeds matter because the company is funding research and development rather than an established commercial product base. The transaction also increases the share count, making financing structure an important part of the investment case.
Losses continue through June
Yarrow reported a net loss of USD 9.3 million for the six months ended June 30, 2026, while cash stood at USD 18.7 million at that date, according to StockTitan. The same filing summary said management expected liquidity to fund operations for at least 12 months.
That contrast defines Yarrow's profile: the offering provides USD 172.5 million of new gross funding, while the six-month loss shows the cost of advancing clinical programs. The financing therefore extends the runway but does not remove development and execution risk.
YB-101 remains the central asset
Yarrow is developing YB-101, an anti-thyroid stimulating hormone receptor antibody for Graves' disease and thyroid eye disease. The company describes the candidate as a potential first-in-class therapy and says it is advancing a Phase 2a/2b program, as reported in its September corporate filing by the SEC.
Market value and listing
Yarrow Bioscience was last quoted at USD 22.52 on Nasdaq on September 30, 2026 at 4:00 p.m. ET. Its market capitalization was USD 209.5 million, and its 52-week range was USD 16.00 to USD 46.95 on the same date.
VYNE and Yarrow Bioscience at a glance
- Company: Yarrow Bioscience Inc
- Ticker: YARW
- Primary exchange: Nasdaq Capital Market
- Market capitalization: USD 209.5 million (as of September 30, 2026)
- 52-week range: USD 16.00-46.95 (as of September 30, 2026)
- Sector / Industry: Healthcare / Biotechnology
